Published online before print September 8, 2008, doi: 10.1161/CIRCULATIONAHA.108.784289
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;118:1347-1357.)
© 2008 American Heart Association, Inc.
Molecular Cardiology |
Suppression of the JNK Pathway by Induction of a Metabolic Stress Response Prevents Vascular Injury and Dysfunction
From the Department of Cardiology, 2nd Medical Clinic of the University Hospital Mainz, Johannes Gutenberg University, Mainz, Germany (E.S., J.D., S.S., A.D., P.W., T.M.), and Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, Mass (S.R.T., K.C., J.F.K.).
Correspondence to Eberhard Schulz, MD, Department of Cardiology, Johannes Gutenberg University, 55101 Mainz, Germany. E-mail dreberhard. schulz{at}nexgo.de
Received April 8, 2008; accepted July 10, 2008.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Oxidative injury and dysfunction of the vascular endothelium are early and causal features of many vascular diseases. Single antioxidant strategies to prevent vascular injury have met with mixed results.
Methods and Results— Here, we report that induction of a metabolic stress response with adenosine monophosphate kinase (AMPK) prevents oxidative endothelial cell injury. This response is characterized by stabilization of the mitochondrion and increased mitochondrial biogenesis, resulting in attenuation of oxidative c-Jun N-terminal kinase (JNK) activation. We report that peroxisome proliferator coactivator 1
is a key downstream target of AMPK that is both necessary and sufficient for the metabolic stress response and JNK attenuation. Moreover, induction of the metabolic stress response in vivo attenuates reactive oxygen species–mediated JNK activation and endothelial dysfunction in response to angiotensin II in wild-type mice but not in animals lacking either the endothelial isoform of AMPK or peroxisome proliferator coactivator 1.
Conclusion— These data highlight AMPK and peroxisome proliferator coactivator 1 as potential therapeutic targets for the amelioration of endothelial dysfunction and, as a consequence, vascular disease.
Key Words: angiotensin • endothelium • hypertension • metabolism
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The vascular endothelium mediates local tissue homeostasis through the regulation of blood flow, coagulation, and trafficking of both macromolecules and inflammatory cells.1 Dysfunction of the endothelium is an early feature of chronic diseases such as atherosclerosis and diabetes, and the presence of endothelial dysfunction predicts future vascular consequences.2,3 These chronic vascular diseases exhibit excess ambient levels of reactive oxygen species (ROS) in the vascular wall that contribute to endothelial injury and dysfunction.4 Attempts to limit endothelial injury and vascular disease via exogenous ROS scavengers have not been proven effective in clinical settings,5 indicating that the mechanisms of oxidative endothelial injury are not well defined.
Clinical Perspective p 1357
One means of cellular protection against injury is caloric restriction; ample data indicate that this intervention not only extends the lifespan of model organisms but also reduces the risk of chronic degenerative diseases.6 However, the exact mechanisms responsible for these effects have not been fully elucidated. Recent efforts in model systems have uncovered a number of caloric restriction "mimetics" that have proved useful in studying metabolic stress. Among these compounds are 2-deoxy glucose and metformin.7 The former is a nonmetabolizable form of glucose that inhibits the phosphohexose isomerase enzyme and extends lifespan in Caenorhabditis elegans.6 Metformin is a drug for improving insulin resistance that induces changes in metabolism and changes in gene expression that closely parallel caloric restriction.6 The specific mechanism(s) whereby caloric restriction and its mimetics provide cellular protection and longevity are not yet clear.
Among the pathways sensitive to nutrient deprivation is the adenosine monophosphate (AMP)–activated protein kinase (AMPK). This ubiquitous kinase is a heterotrimeric enzyme consisting of , β, and 
subunits that is sensitive to the cellular AMP:ATP ratio and consequently plays a pivotal role in cellular adaptation to energy stress.8 Activation of AMPK attenuates anabolic processes such as the synthesis of proteins, fatty acids, and cholesterol, and it stimulates ATP-generating catabolic pathways.9 Accordingly, downstream targets of AMPK include key enzymes of glucose and lipid metabolism,10 mitochondrial enzymes,11 and transcriptional coactivators controlling mitochondrial biogenesis.12 The precise role of AMPK and its molecular targets in more generalized stress responses, however, is not well defined.8 Therefore, the purpose of this study was to examine the implications of AMPK in mediating the response to oxidative stress, a key feature of many chronic diseases.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
Cell culture reagents were obtained from Invitrogen (Carlsbad, Calif) and Cambrex (East Rutherford, NJ). 5-Aminoimidazole-4-carboxamide riboside (AICAR) was obtained from Toronto Research Chemicals (Toronto, Canada). Tumor necrosis factor alpha-
(TNF-) was purchased from R&D systems (Minneapolis, Minn). Compound C was a kind gift from Merck. Polyclonal antibodies against phospho-AMPK (Thr-172), -AMPK, and phospho-acetyl CoA carboxylase (ACC; Ser-79) were from Cell Signaling Technology (Beverly, Mass). We obtained antibodies for catalase and mitochondrial transcription factor A from Abcam (Cambridge, Mass) and the heme oxygenase-1 antibody from Stressgen (Victoria, BC, Canada). Antibodies against ACC, 1-AMPK, 2-AMPK, superoxide dismutase (SOD) 1, and SOD2 were from Upstate Biotechnology (Lake Placid, NY), as well as the small interfering RNA (siRNA) constructs SMARTPool with controls. [32P]-ATP (250 µCi, 10 mCi/mL) was obtained from Perkin Elmer Life Sciences (Boston, Mass). Dihydrorhodamine, JC-1, nonyl acridine orange (NAO), and MitoTracker Green FM were purchased from Molecular Probes (Eugene, Ore). Lipopolysaccharide (Escherichia coli stereotype 0128:B12) and all other reagents were obtained from Sigma (St Louis, Mo).
Adenoviruses
The adenoviral vector expressing a dominant-negative 2-AMPK mutant was a kind gift of Dr Morris J. Birnbaum (University of Pennsylvania).13 The adenoviral vector expressing PGC-1 was a kind gift by Dr Bruce M. Spiegelman (Dana-Farber Cancer Institute). Cells were typically infected at a multiplicity of infection of 10 to 50, and control adenovirus consisted of a LacZ construct at the same multiplicity of infection.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were cultured in EGM-2 medium (Clonetics) with all supplements and used between passages 3 and 6. Four hours before AMPK activation, HUVECs were cultivated in a reduced-serum medium containing 0.4% FBS with all EGM-2 supplements in a 1:5 dilution. COS-7 cells were cultured in DMEM (Gibco, Invitrogen) supplemented with 10% FBS, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin. For experiments, confluent cells were used on either 6-well or 12-well plates. Porcine aortic endothelial cells (PAECs) were cultured as described.14 Overnight, AICAR (1 mmol/L) or metformin (5 mmol/L) treatment was directly added to the cell medium, and before H2O2 exposure, cells were washed in HEPES-buffered physiological salt solution (PSS) as described.14
Cellular ATP Content and AMPK Activity Assay
Measurement of ATP was performed with the bioluminescent somatic cell assay kit (Sigma) according to instructions. Determination of AMPK catalytic activity was performed by incorporation of [32P] into the specific AMPK target sequence HMRSAMSGLHLVKRR (SAMS peptide) as described previously.15
Mitochondrial ROS Production
Mitochondrial ROS production was assessed by measuring dihydrorhodamine 123 fluorescence. After treatments, PAECs were washed and incubated for 30 minutes with 10 µmol/L dihydrorhodamine in PSS, washed in PSS, and treated with 200 µmol/L H2O2 for 30 minutes. Cells were then washed, scraped in ice-cold PBS, and dispersed by repeated pipetting, and aliquots were added to either coverslips or 96-well plates. Dihydrorhodamine fluorescence was assessed with a fluorescent plate reader (Molecular Devices, Sunnyvale, Calif) with excitation at 480 nm and emission at 535 nm.
Mitochondrial Membrane Potential
Mitochondrial membrane potential was estimated by fluorescence of JC-1 aggregates that are formed as a function of inner mitochondrial membrane potential.16 PAECs were washed twice with PSS, equilibrated for 30 minutes, and then treated with H2O2 or vehicle for 1 hour. After treatment, cells were carefully washed 2 times and incubated with 2.5 µg/mL JC-1 for 15 minutes in PSS, washed 3 times in PSS, and subjected to fluorescence (for red fluorescence: excitation, 550 nm; emission, 600 nm; for green fluorescence: excitation, 485 nm; emission, 535 nm) ratio detection.
Transcriptional Activation Assays and Immunoblotting
All experiments were performed with the Dual Luciferase Reporter Assay (Promega, San Luis Obispo, Calif) with an internal Renilla-luciferase control plasmid to normalize for transfection efficiencies. COS-7 cells were transiently transfected for 40 hours with the human mitochondrial transcription factor A luciferase promoter as described.17 Immunoblotting was performed as previously described.14
Cell Death Assays
PAECs in 12-well plates were treated with vehicle, AICAR, or metformin overnight in regular medium. Cells were then kept in HEPES-buffered PSS (30 minutes) and exposed to increasing concentrations of H2O2 for 2 hours. For the lactate dehydrogenase (LDH) release assay, we used the cytotoxicity detection kit (Roche Applied Science, Indianapolis, Ind) normalized to 1 well treated with 1% Triton X-100 for maximum LDH release. Cell viability was also assessed by the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) following the manufacturer’s instructions. Briefly, the tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) is bioreduced by metabolically active cells into a formazan product and can be measured by the amount of 490 nm absorbance in the tissue media.
Mitochondrial Mass Determination
Mitochondrial mass was estimated by fluorescence of NAO or MitoTracker Green FM, both mitochondrial specific dyes, independently of the mitochondrial membrane potential.18,19 After various treatments, HUVECs were washed twice with PBS and then incubated in full growth medium including 100 nmol/L NAO or MitoTracker Green FM for 30 minutes at 37°C and 5% CO2. After 3 washes, cells were subjected to fluorescence detection (for MitoTracker Green FM: excitation, 490 nm; emission, 516 nm; for NAO: excitation, 495 nm; emission, 519 nm) as an indicator of mitochondrial mass.
Gene Silencing by siRNA
Double-stranded RNAi was transfected into cells with RNAiFect (Qiagen, Valencia, Calif). After 72 hours of transfection, cells were incubated with 1 mmol/L AICAR overnight for chronic AMPK activation. Then, 100 µmol/L H2O2 for 2 hours was applied to the cells for cell death and cell survival assays. Scrambled RNAi (Upstate Biotechnology Inc, Waltham, Mass) was used as control.
Experimental Animals
Animal experiments were in accordance with the Declaration of Helsinki and National Institutes of Health guidelines and were performed with approval of the Ethics Committee of the University Hospital Mainz. To study in vivo AMPK activation by AICAR, we used male C57Bl6 mice. The mice were anesthetized by isoflurane inhalation and treated with a subcutaneous osmotic minipump (Alzet model 1007) containing either angiotensin II or solvent (NaCl 0.9%) for 7 days. Angiotensin infusion rate averaged 1 mg · kg–1 · d–1. Animals from both groups were randomized to receive either AICAR (200 mg · kg–1 · d–1) or vehicle (NaCl 0.9%) via subcutaneous injection once daily, starting at the time of the angiotensin II–containing minipump implantation. To probe the role of AMPK, we used 100 1-AMPK knockout mice20 and corresponding littermate wild-type mice (C57Bl6/129Sv/FVB-N background) as controls. To probe the role of PGC-1, we used animals with severely diminished PGC-1 levels as described previously.21 In a second approach, endothelial dysfunction was induced in wild-type mice by a single intraperitoneal injection of lipopolysaccharide (15 mg/kg), and the mice were killed 24 hours later. Mice were randomized to receive either AICAR (200 mg · kg–1 · d–1) or vehicle (NaCl 0.9%) via subcutaneous injection once daily, starting 2 days before lipopolysaccharide treatment. To dissect the role of AMPK, lipopolysaccharide/AICAR injections also were performed in 1-AMPK knockout mice. After all treatment protocols, animals were killed, and tissues were removed and subjected to further analysis.
Assessment of Endothelial Function and Superoxide
Endothelial function was assayed as endothelium-dependent arterial relaxation in segments of thoracic aorta as described previously.22 Vascular superoxide was estimated with dihydroethidium staining,23 and NADPH-oxidase activity was estimated in heart membrane fractions as described.22
Statistical Analysis
All immunoblots are representative of 3 to 4 independent experiments. Numerical data are presented as mean±SEM. Comparisons among treatment groups were performed with 1-way ANOVA and an appropriate posthoc Dunnett or Tukey comparison. Statistical significance was accepted if the null hypothesis was rejected with values of P<0.05.
All authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Peroxide Induces AMPK Activation in the Endothelium
Because AMPK isoform composition is known to affect its function in various cell types,24,25 we used reverse-transcriptase polymerase chain reaction and immunoblotting to determine that endothelial cells almost exclusively harbor the
1 catalytic isoform (Figures IA and IB of the online Data Supplement). There is also a predominance of the β1 and 2 isoforms (Figure IA). We then treated endothelial cells with H2O2 and observed concentration-dependent AMPK activation as assessed by Western blot and AMPK activity assay (Figure 1A and 1B). Inhibitors targeting phosphoinositide 3-kinase, protein kinase C, src-family kinases, general tyrosine kinases, mitogen-activated protein kinases, or intracellular calcium transients did not block H2O2-induced AMPK activation (data not shown). We next examined cellular energy status and found that endothelial ATP levels decline rapidly after H2O2 exposure (Figure 1C), suggesting that AMPK activation is, at least in part, mediated by the resulting rise in cellular AMP that can allosterically activate AMPK.26
|
To determine whether AMPK activation promotes survival, we inhibited H2O2-mediated AMPK activation with compound C but observed no impact on cell death (Figure 1D). Similarly, overexpression of a dominant-negative AMPK mutant had no impact on H2O2-mediated cell death (Figure 1E) despite significant inhibition of AMPK activation (Figure 1F). These data indicate that acute AMPK activation has limited implications for endothelial cell death in response to H2O2.
Chronic AMPK Activation Induces Stress Adaptation in Endothelium
We were able to elicit sustained endothelial cell AMPK activation with AICAR treatment over 20 hours on the basis of AMPK activity and phosphorylation of its downstream target, ACC (Figure 2A and 2B). This chronic AMPK activation before H2O2 challenge produced a significant attenuation in the response to H2O2 that was reversed by either pharmacological (Figure 2C) or molecular (Figure 2D) inhibition of AMPK. Shorter AICAR treatment for 30 minutes or 4 hours did not mimic the effects observed with a 20-hour treatment period (supplementary Figure II). To determine the general nature of these findings, we chronically activated AMPK with the drug metformin (Figure 2E)27 and observed a significant inhibition of H2O2-induced cell death that was quantitatively similar to that observed with AICAR (Figure 2F). Thus, chronic AMPK activation attenuates H2O2-induced endothelial cell death.
|
P<0.05 vs AICAR by 2-way ANOVA. Cells were then treated with H2O2, and either cell death or viability was determined as indicated by LDH release or MTS assay, respectively. E, PAECs were treated with metformin as indicated, and AMPK activity was determined in cell lysates as 32P incorporation into the SAMS peptide as described in Methods. *P<0.05 vs 0 mmol/L by 1-way ANOVA with a posthoc Dunnett test. F, PAECs were treated with 1 mmol/L metformin or AICAR before a 2-hour exposure to H2O2 as indicated, and cell death was determined by LDH release. *P<0.05 vs control (CTL) 50 µmol/L H2O2;
AMPK-Mediated Stress Adaptation Involves the Mitochondrion
Cell viability after H2O2 exposure is, in part, dictated by the relative activity of death versus survival pathways.28 We probed Akt and mitogen-activated protein (MAP) kinase activation and found that AICAR and metformin had no impact on H2O2-induced Akt or P38 MAP kinase activation (Figure 3A), whereas c-Jun N-terminal kinase (JNK) activation determined as c-Jun phosphorylation was abrogated by AMPK (Figure 3A).29 We did not find any change in cytosolic antioxidant enzymes with AICAR or metformin; however, we did detect a 30% to 40% increase in mitochondrial SOD (Figure 3B and supplementary Figure III).
|
Because JNK is a downstream component of mitochondrial death signals30 and AMPK activation increased mitochondrial SOD, we explored the implications of chronic AMPK activation for mitochondrial response(s) to toxic stimuli. Endothelial cell H2O2 treatment reduced mitochondrial membrane potential, and chronic AMPK activation with AICAR (Figure 3C and 3D) or metformin (not shown) prevented this effect. Similarly, the H2O2-induced mitochondrial ROS signal determined by dihydrorhodamine fluorescence was attenuated by chronic AMPK activation with either metformin or AICAR (Figure 3E). We also could mimic the effect of AICAR to suppress the mitochondrial ROS signal and JNK activation in response to H2O2 using the mitochondria-targeted antioxidant MitoQ14,31 (Figure 3F and 3G). Collectively, these data indicate that chronic AMPK activation modifies mitochondrial responses to H2O2.
Chronic AMPK Activation Induces PGC-1–Dependent Mitochondrial Biogenesis
One recognized link between AMPK and the mitochondrion is mitochondrial biogenesis12 that appears dependent on PGC-1 in many tissues.32 In agreement with these data, AICAR treatment increased the abundance of markers associated with mitochondrial biogenesis such as PGC-1, mitochondrial transcription factor A, and cytochrome c (Figure 4A and supplementary Figure IV). Consistent with this observation, AICAR treatment produced PGC-1–driven gene transcription assessed by the mitochondrial transcription factor A promoter linked to luciferase (Figure 4B).32 Similarly, chronic AMPK activation produced an increase in endothelial cell mitochondrial mass (Figure 4C), and this effect was recapitulated with adenoviral overexpression of PGC-1 (Figure 4D and 4E). Finally, AICAR stimulation increased mitochondrial mass in an 1-AMPK– and PGC-1–dependent manner (Figure 4F). Collectively, these data indicate that chronic AMPK activation increases endothelial cell mitochondrial biogenesis and mass.
|
Stimulation of Mitochondrial Biogenesis Enhances Endothelial Cell Resistance to H2O2
The endothelial cell resistance to H2O2-induced death and dysfunction afforded by AMPK extended beyond H2O2 because TNF-–induced cell death (measured as JNK activation; Figure 5A) also was inhibited by AMPK. Because we believed that the action of AICAR and metformin involved the mitochondrion (Figure 3) and that AMPK facilitates mitochondrial biogenesis (Figure 4), we examined the link between mitochondrial biogenesis and endothelial cell resistance to stress. We found that AMPK activation reduced H2O2-induced cell death, and this response was recapitulated with PGC-1 overexpression via adenoviral transfection (Figure 5B and 5C). The effect of AICAR against H2O2-mediated cell death was lost by siRNA-mediated suppression of either 1-AMPK or PGC-1 (Figure 5D and 5E). We also found that overexpression of PGC-1 selectively attenuates H2O2-induced JNK activation with preserved p38 MAP kinase activation (Figure 5F). In total, these data link stimulation of mitochondrial biogenesis to endothelial cell protection from cell death and indicate that PGC-1 overexpression is both necessary and sufficient for this response.
|
In Vivo AMPK Activation Prevents Endothelial Dysfunction in a PGC-1–Dependent Manner
To determine whether our cell culture data are operative in vivo, we used a model of angiotensin infusion that produces vascular dysfunction, in part, through increased vascular oxidative stress via ROS production.33 Accordingly, we induced endothelial dysfunction in mice with a 7-day infusion of angiotensin II. Aortas were harvested and examined for endothelial function as acetylcholine-induced endothelium-dependent arterial relaxation. We found that angiotensin II–induced endothelial dysfunction (Figure 6A) was characterized by an increased superoxide signal in media of the thoracic aorta (Figure 6B), increased myocardial NADPH oxidase activity (Figure 6C),33 and JNK activation (Figure 6D). In this model, chronic AMPK activation with AICAR attenuated endothelial dysfunction (Figure 6A) and NADPH oxidase activation (Figure 6B and 6C) without material alteration in the blood pressure response (supplementary Figure V). Moreover, AICAR was ineffective in preserving endothelial function in mice lacking either the 1-AMPK isoform (Figure 6E) or PGC-1 (Figure 6F), validating our paradigm in vivo.
|
To determine whether chronic AMPK activation was generally protective, we used a lipopolysaccharide-induced model of endothelial dysfunction.34 Treatment of mice with lipopolysaccharide induced both endothelial dysfunction (Figure 7A) and an increased vascular superoxide signal (Figure 7B) that were prevented by chronic AMPK activation in wild-type but not 1-AMPK–null mice. Thus, taken together, these data indicate that chronic AMPK activation in vivo also protects the endothelium against the injurious actions of angiotensin II and lipopolysaccharide.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this study, we found that induction of metabolic stress in the form of chronic AMPK activation was highly effective in protecting endothelial cells against both H2O2 and TNF-
. This stress resistance was related to AMPK-mediated modulation of the mitochondrial redox state that was dependent on the transcriptional coactivator PGC-1. Indeed, PGC-1 was sufficient for this response as determined by overexpression of PGC-1, and the redox modulation was mimicked by a mitochondria-targeted antioxidant. We also found that the AMPK–PGC-1 pathway selectively attenuated stress-related JNK activation, an effect one might expect to suppress stress-related cellular injury and death. Our findings were physiologically relevant because metabolic stress induction via AICAR in vivo prevented angiotensin II–mediated JNK activation and endothelial injury, a process dependent on oxidative stress and vascular ROS production.35 Moreover, lipopolysaccharide-induced endothelial dysfunction also was prevented by chronic AMPK activation. This protective effect of AICAR was lost in mice lacking 1-AMPK (the isoform that predominates in the endothelium) and PGC-1. Thus, these data indicate that AMPK can direct adaptive changes in the mitochondrion via PGC-1, which enhances mitochondrial biogenesis and cellular resistance to stress. Previous studies addressing the role of AMPK in cell death have yielded equivocal results.36–38 Some of these previous negative studies relied solely on AICAR as the means to increase AMPK activity.36,38 However, AICAR may affect other AMP-dependent enzymes, and long-term AICAR treatment might increase cellular nucleotide levels.39 In this study, we used metformin as a complementary means of AMPK activation and found comparable effects on endothelial cell survival. Because the mechanism of metformin-mediated AMPK activation differs from that of AICAR,40 there is confidence that the results with AICAR are indeed due to AMPK activation. This contention is supported by our observations that both genetic and pharmacological approaches to block AICAR-mediated AMPK activation reversed the protective effects of AICAR in vitro and in vivo.
It is now clear that different AMPK isoform compositions may dictate distinct sequelae of AMPK activation. For example, metabolic consequences of AMPK activation such as insulin sensitivity25 have largely been attributed to the 2 isoform. The AMP dependency of AMPK is also greater in 2-bearing enzyme complexes.41 Moreover, differences in substrate specificity have been observed for the 2 -subunits in vitro.24 Thus, the fact that endothelial cells exclusively harbor the 1-AMPK isoform may indicate a functional role distinct from the well-characterized metabolic features of AMPK. For example, one could speculate that the 1-AMPK enzyme is protective against cell death, whereas 2-containing enzymes might promote it. In this regard, studies in neuronal or pancreatic cells (with a preponderance of the 2 isoform) exhibit increased cell death on AMPK activation,42 whereas data presented here and another study in endothelial cells (with the 1 isoform) show that AMPK activation is cytoprotective.37
In the present study, we found that AMPK activation induced mitochondrial biogenesis in the endothelium, consistent with reports from skeletal muscle.12 A previous report suggests that modulation of nitric oxide levels in endothelium parallel PGC-1–dependent mitochondrial biogenesis.43 Because previous in vivo data implicate endothelial nitric oxide synthase–derived nitric oxide in mitochondrial biogenesis,44 it is tempting to speculate that our effects with AICAR are due to endothelial nitric oxide synthase activation. Such speculation would be consistent with reports that AMPK is responsible for vascular endothelial growth factor–mediated endothelial nitric oxide synthase activation.45 However, recent data that AMPK directly phosphorylates PGC-146 would seem to refute the requirement for nitric oxide production. Understanding the precise details of AMPK-mediated PGC-1 activation in the endothelium requires further investigation.
Signaling cascades that lead to cell death often require mitochondrial ROS production and a loss of mitochondrial membrane potential.47 We have implicated stabilization of the mitochondrial membrane potential and reduced mitochondrial ROS as key targets for metabolic stress–mediated prevention of endothelial cell death. Our findings implicate PGC-1 in this process and provide a mechanism whereby the observed contribution of PGC-1 to cellular oxidant defense leads to attenuation of cell death.48 Indeed, the fact that a mitochondria-targeted antioxidant (MitoQ) also limits stress-induced mitochondrial ROS and cell death supports our contention that the mitochondrion is a key component of AMPK-mediated protection.
Our data indicate that metabolic stress provides cellular protection, at least in part, through the attenuation of JNK activation. It is well known that JNK mediates apoptosis and cell death in response to environmental stress;49 thus, it is plausible that the salutary effects of metabolic stress stem from JNK inhibition. However, the specific means whereby AMPK and PGC-1 signaling impact JNK is not yet clear. One possibility relates to observations that prolonged JNK activation requires intracellular ROS, which inactivates JNK phosphatases.50 In our study, we found that AMPK activation attenuated intracellular and mitochondrial ROS signals, perhaps preventing the phosphatase inhibition needed for JNK activation. Published data indicate that manganese SOD prevents TNF-–induced JNK activation,50 consistent with our findings that AMPK increases endothelial cell manganese SOD content. Thus, suppression of intracellular ROS appears to be a plausible explanation for our findings that AMPK and PGC-1 attenuate endothelial JNK activation and injury.
The present study has important implications for endothelial cell biology. Oxidative stress is a common feature of many vascular diseases and is known to impair endothelial function. Indeed, endothelial damage and reendothelialization are important factors that determine endothelial function. In this context, the endothelium has emerged as a target for the development of new therapies for vascular disease. However, the implications of increased oxidative stress on endothelial cell viability have garnered surprisingly little attention. We show here that moderate levels of oxidative stress (
10 µmol/L H2O2) lead to significant endothelial cell necrosis; thus, it seems reasonable that finding new molecular targets to limit endothelial cell death should favorably affect vascular disease. Our study identifies PGC-1, a key regulator of mitochondrial biogenesis, as a potential molecular target to improve endothelial cell viability and function in vascular disease.
|
Acknowledgments |
|---|
We thank Ana Sharma and Nikhiel Rau for excellent technical assistance.
Sources of Funding
This work was supported by National Institutes of Health grants HL081587, HL68758, and HL67206 (to Dr Keaney) and Deutsche Forschungsgemeinschaft grants SCHU 1486/1–1 and SCHU 1486/2–1 (to Dr Schulz).
Disclosures
None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007; 7: 803–815.[CrossRef][Medline] [Order article via Infotrieve]
2. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003; 42: 1149–1160.
3. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events inpatients with peripheral vascular disease. J Am Coll Cardiol. 2003; 41: 1769–1775.
4. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993; 91: 2546–2651.[Medline] [Order article via Infotrieve]
5. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 154–160.
6. Sinclair DA. Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev. 2005; 126: 987–1002.[CrossRef][Medline] [Order article via Infotrieve]
7. Ingram DK, Anson RM, de Cabo R, Mamczarz J, Zhu M, Mattison J, Lane MA, Roth GS. Development of calorie restriction mimetics as a prolongevity strategy. Ann N Y Acad Sci. 2004; 1019: 412–423.[CrossRef][Medline] [Order article via Infotrieve]
8. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003; 144: 5179–5183.
9. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007; 8: 774–785.[CrossRef][Medline] [Order article via Infotrieve]
10. Carling D, Hardie DG. The substrate and sequence specificity of the AMP-activated protein kinase: phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta. 1989; 1012: 81–86.[Medline] [Order article via Infotrieve]
11. Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol. 2000; 88: 2219–2226.
12. Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A. 2002; 99: 15983–15987.
13. Mu J, Brozinick JT Jr, Valladares O, Bucan M, Birnbaum MJ. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell. 2001; 7: 1085–1094.[CrossRef][Medline] [Order article via Infotrieve]
14. Chen K, Thomas SR, Albano A, Murphy MP, Keaney JF Jr. Mitochondrial function is required for hydrogen peroxide-induced growth factor receptor transactivation and downstream signaling. J Biol Chem. 2004; 279: 35079–35086.
15. Schulz E, Anter E, Zou MH, Keaney JF Jr. Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation. 2005; 111: 3473–3480.
16. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, Steele GD Jr, Chen LB. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A. 1991; 88: 3671–3675.
17. Gleyzer N, Vercauteren K, Scarpulla RC. Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol. 2005; 25: 1354–1366.
18. Maftah A, Petit JM, Ratinaud MH, Julien R. 10-N nonyl-acridine orange: a fluorescent probe which stains mitochondria independently of their energetic state. Biochem Biophys Res Commun. 1989; 164: 185–190.[CrossRef][Medline] [Order article via Infotrieve]
19. Metivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I, Kroemer G. Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett. 1998; 61: 157–163.[CrossRef][Medline] [Order article via Infotrieve]
20. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Flamez D, Mu J, Wojtaszewski JF, Schuit FC, Birnbaum M, Richter E, Burcelin R, Vaulont S. Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans. 2003; 31 (pt 1): 216–219.[Medline] [Order article via Infotrieve]
21. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005; 3: e101.[CrossRef][Medline] [Order article via Infotrieve]
22. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, Ullrich V, Mulsch A, Schulz E, Keaney JF Jr, Stamler JS, Munzel T. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004; 113: 482–489.[CrossRef][Medline] [Order article via Infotrieve]
23. Chen Z, Keaney JF Jr, Schulz E, Levison B, Shan L, Sakuma M, Zhang X, Shi C, Hazen SL, Simon DI. Decreased neointimal formation in Nox2-deficient mice reveals a direct role for NADPH oxidase in the response to arterial injury. Proc Natl Acad Sci U S A. 2004; 101: 13014–13019.
24. Woods A, Salt I, Scott J, Hardie DG, Carling D. The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett. 1996; 397: 347–351.[CrossRef][Medline] [Order article via Infotrieve]
25. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, Bennoun M, Gomas E, Nicolas G, Wojtaszewski JF, Kahn A, Carling D, Schuit FC, Birnbaum MJ, Richter EA, Burcelin R, Vaulont S. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest. 2003; 111: 91–98.[CrossRef][Medline] [Order article via Infotrieve]
26. Carling D, Clarke PR, Zammit VA, Hardie DG. Purification and characterization of the AMP-activated protein kinase: copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem. 1989; 186: 129–136.[Medline] [Order article via Infotrieve]
27. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108: 1167–1174.[CrossRef][Medline] [Order article via Infotrieve]
28. Wang X, McCullough KD, Franke TF, Holbrook NJ. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem. 2000; 275: 14624–14631.
29. Chen K, Vita JA, Berk BC, Keaney JF Jr. c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves SRC-dependent EGF receptor transactivation. J Biol Chem. 2001; 276: 16045–16050.
30. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000; 288: 870–874.
31. Smith RA, Kelso GF, Blaikie FH, Porteous CM, Ledgerwood EC, Hughes G, James AM, Ross MF, Asin-Cayuela J, Cocheme HM, Filipovska A, Murphy MP. Using mitochondria-targeted molecules to study mitochondrial radical production and its consequences. Biochem Soc Trans. 2003; 31 (pt 6): 1295–1299.[Medline] [Order article via Infotrieve]
32. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999; 98: 115–124.[CrossRef][Medline] [Order article via Infotrieve]
33. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/HADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996; 97: 1916–1923.[Medline] [Order article via Infotrieve]
34. Bachschmid M, Thurau S, Zou MH, Ullrich V. Endothelial cell activation by endotoxin involves superoxide/NO-mediated nitration of prostacyclin synthase and thromboxane receptor stimulation. FASEB J. 2003; 17: 914–916.
35. Keaney JF Jr. Oxidative stress and the vascular wall: NADPH oxidases take center stage. Circulation. 2005; 112: 2585–2588.
36. Campas C, Lopez JM, Santidrian AF, Barragan M, Bellosillo B, Colomer D, Gil J. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood. 2003; 101: 3674–3680.
37. Ido Y, Carling D, Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes. 2002; 51: 159–167.
38. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Esumi H. ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene. 2003; 22: 6177–6182.[CrossRef][Medline] [Order article via Infotrieve]
39. Longnus SL, Wambolt RB, Parsons HL, Brownsey RW, Allard MF. 5-Aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol Regul Integr Comp Physiol. 2003; 284: R936–R944.
40. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 2002; 51: 2420–2425.
41. Salt I, Celler JW, Hawley SA, Prescott A, Woods A, Carling D, Hardie DG. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J. 1998; 334 (pt 1): 177–187.[Medline] [Order article via Infotrieve]
42. Jung JE, Lee J, Ha J, Kim SS, Cho YH, Baik HH, Kang I. 5-Aminoimidazole-4-carboxamide-ribonucleoside enhances oxidative stress-induced apoptosis through activation of nuclear factor-kappaB in mouse Neuro 2a neuroblastoma cells. Neurosci Lett. 2004; 354: 197–200.[CrossRef][Medline] [Order article via Infotrieve]
43. Borniquel S, Valle I, Cadenas S, Lamas S, Monsalve M. Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1alpha. FASEB J. 2006; 20: 1889–1891.
44. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, Carruba MO. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003; 299: 896–899.
45. Reihill JA, Ewart MA, Hardie DG, Salt IP. AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. Biochem Biophys Res Commun. 2007; 354: 1084–1088.[CrossRef][Medline] [Order article via Infotrieve]
46. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A. 2007; 104: 12017–12022.
47. Gottlieb E, Vander Heiden MG, Thompson CB. Bcl-x(L) prevents the initial decrease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol. 2000; 20: 5680–5689.
48. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006; 127: 397–408.[CrossRef][Medline] [Order article via Infotrieve]
49. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000; 103: 239–252.[CrossRef][Medline] [Order article via Infotrieve]
50. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 2005; 120: 649–661.[CrossRef][Medline] [Order article via Infotrieve]
|
Footnotes |
|---|
*The first 2 authors contributed equally to this work.
Guest Editor for this article was Aruni Bhatnagar, PhD.
The online-only Data Supplement is available with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.108.784289/DC1.
Related Article:
Circulation 2008 118: 1307-1308.
This article has been cited by other articles:
 |
|
 |
|
  Z. Ungvari, N. Labinskyy, P. Mukhopadhyay, J. T. Pinto, Z. Bagi, P. Ballabh, C. Zhang, P. Pacher, and A. Csiszar Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1876 - H1881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Xu and M.-H. Zou Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction Circulation, September 29, 2009; 120(13): 1266 - 1286. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fisslthaler and I. Fleming Activation and Signaling by the AMP-Activated Protein Kinase in Endothelial Cells Circ. Res., July 17, 2009; 105(2): 114 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Peterson, D. H. Kim, M. Li, V. Positano, L. Vanella, L. F. Rodella, F. Piccolomini, N. Puri, A. Gastaldelli, C. Kusmic, et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice J. Lipid Res., July 1, 2009; 50(7): 1293 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Csiszar, N. Labinskyy, J. T. Pinto, P. Ballabh, H. Zhang, G. Losonczy, K. Pearson, R. de Cabo, P. Pacher, C. Zhang, et al. Resveratrol induces mitochondrial biogenesis in endothelial cells Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H13 - H20. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||